Riddi Vinesia L, Harahap Edward U, Sitinjak David, Nirmawati Ros
Department of Anatomical Pathology, Dharmais Cancer Hospital-National Cancer Center, Jakarta, IDN.
Department of Urology, Dharmais Cancer Hospital-National Cancer Center, Jakarta, IDN.
Cureus. 2025 Jun 14;17(6):e86000. doi: 10.7759/cureus.86000. eCollection 2025 Jun.
Ductal adenocarcinoma of the prostate (PDA) is a rare and aggressive variant of prostate cancer with a tendency for advanced local invasion and atypical metastatic spread. We report a case of a 54-year-old male presenting with urinary symptoms and significant weight loss. Imaging revealed a pelvic mass involving the prostate and bladder, with bone metastases to the pelvis and femur. Histopathological examination of transurethral resection specimens demonstrated ductal architecture. Immunohistochemistry showed α-Methylacyl-CoA racemase (AMACR) positivity, patchy cytokeratin 7 (CK7) expression, and negative prostate-specific antigen (PSA) and GATA-binding protein 3 (GATA3). Despite the unusual immunohistochemistry profile, the findings supported a diagnosis of PDA. The patient received radiotherapy and hormonal treatment, resulting in a marked PSA decline (PSA levels declined from 19.94 ng/mL to 0.34 ng/mL over eight months, representing a reduction of approximately 98.3%). This case highlights the diagnostic complexity of PDA, particularly when immunohistochemical findings deviate from classical patterns, and underscores the need for an integrated diagnostic approach in managing aggressive prostate cancer variants.
前列腺导管腺癌(PDA)是前列腺癌中一种罕见且侵袭性强的变异类型,具有局部侵袭进展和非典型转移扩散的倾向。我们报告一例54岁男性,表现为泌尿系统症状和明显体重减轻。影像学检查发现盆腔肿块累及前列腺和膀胱,并伴有骨盆和股骨骨转移。经尿道切除标本的组织病理学检查显示为导管结构。免疫组织化学显示α-甲基酰基辅酶A消旋酶(AMACR)阳性、细胞角蛋白7(CK7)呈散在表达,前列腺特异性抗原(PSA)和GATA结合蛋白3(GATA3)阴性。尽管免疫组织化学表现不寻常,但这些结果支持PDA的诊断。该患者接受了放疗和激素治疗,导致PSA显著下降(八个月内PSA水平从19.94 ng/mL降至0.34 ng/mL,下降了约98.3%)。该病例突出了PDA的诊断复杂性,尤其是当免疫组织化学结果偏离经典模式时,并强调了在处理侵袭性前列腺癌变异类型时采用综合诊断方法的必要性。